EW — Edwards Lifesciences Corporation

Q2 2026 adjusted EPS of $0.78 beat the ~$0.74-0.75 consensus, revenue of $1.74B exceeded expectations, and management raised full-year 2026 organic growth guidance to 10%-11% while reaffirming adjusted EPS of $2.95-$3.05. Analysts reacted positively: Leerink upgraded to Outperform, multiple banks raised price targets into the $101-$110 range, and the consensus rating is Buy with zero sell ratings. The technical picture is neutral rather than overbought, so the bullish sentiment has not been fully chased.

Revenue has accelerated over the past year: YoY growth was 14.7% in Q3 2025, 13.3% in Q4 2025, 16.7% in Q1 2026, and 13.6% in Q2 2026, when revenue reached $1.74B and TAVR grew 10.5% in constant currency. Operating margins are stable-to-strong: Q2 2026 came in at 29.8% and Q1 2026 at 31.2%, versus roughly 28% in the year-ago quarters; Q4 2025's 23.6% was a seasonal/charge-related dip rather than a trend. GAAP net income is lumpy due to one-off items, so the cleanest read is revenue and operating profit, both trending up. TTM free cash flow is roughly $1.43B, with Q2 2026 alone generating $585M of FCF.

On trailing GAAP numbers, EW looks expensive at 51.7x P/E, but that is distorted by a low TTM EPS of $1.74 that includes one-off items. On forward adjusted EPS of about $3.00, the stock trades at roughly 30x forward earnings, below its own 5-year average P/E of 34.8x and below its 5-year average P/S of 9.92x (current P/S is 7.95x). For a 78%-gross-margin franchise guiding 10%-11% organic growth, ~30x forward earnings is a premium but not an unreasonable one. The PEG ratio is not meaningful here because trailing earnings growth is distorted by non-recurring items.

At $89.95, the market is paying about 30x forward EPS of $3.00, which already assumes continued high-single-digit TAVR growth and a meaningful TMTT ramp. If Q3 2026 is in line and guidance holds, a 32-34x forward multiple puts fair value at $96-$102; if execution slips, a de-rate toward 27x forward would imply roughly $81. In other words, the stock is pricing in solid execution but not a blowout, so the playbook is to buy on pullbacks toward the 50-day SMA and let the TMTT and asymptomatic-TAVR optionality play out into 2027.

As of 2026-08-27, RSI-14 was 50.4, right in the middle of the range—neither overbought nor oversold. Price was 0.67% below its 20-day SMA, 0.71% above its 50-day SMA, and 6.08% above its 200-day SMA, so the broader trend is still up but near-term momentum has flattened. The stock is effectively range-bound between support near $85 and resistance at the $96.29 52-week high. The entry implication is to wait for a pullback into the $85-$87 zone or a confirmed breakout above $96.29 rather than chasing the middle of the range.

• Aging demographics and expanding structural-heart indications are the main secular demand tailwind for TAVR and TMTT.
• Hospital staffing and procedure volumes have normalized, supporting cardiac device utilization through 2025-2026.
• Interest rates remain a swing factor for high-multiple growth medtech; lower long-term rates would support EW's multiple, while higher rates would pressure it.
• Foreign exchange remains a modest headwind, with constant-currency TAVR growth running ahead of reported growth.
• Competitive dynamics in TAVR from Medtronic, Abbott, and Boston Scientific could create pricing pressure as the market matures.

• Q3 2026 earnings, expected late October 2026, will test whether Edwards can sustain its raised growth guidance against tougher year-over-year comparables.
• Late-breaking TAVR data in asymptomatic patients and TMTT clinical updates at TCT or AHA could expand the addressable market and validate label-expansion optionality.
• TMTT revenue ramp toward the $760-$780M full-year guidance range, with new product launches driving incremental growth.
• Potential regulatory or reimbursement advances supporting structural-heart procedure volumes.

• TAVR growth deceleration or share loss to competitors as the market matures and pricing pressure increases.
• Roughly 30x forward earnings leaves limited room for a guidance miss or a valuation-driven de-rating.
• GAAP earnings volatility from one-off charges, amortization, tax items, or impairments can create periodic headline noise and selloffs.
• TMTT may scale more slowly than expected or face clinical, regulatory, or reimbursement setbacks.
• FX volatility and hospital utilization swings could pressure reported revenue and margins.

Edwards is a best-in-class structural heart franchise with accelerating revenue, durable 78% gross margins, a fortress balance sheet, and a strong pipeline of catalysts. The stock is not cheap on an absolute basis, but at roughly 30x forward EPS with 10%-11% organic growth guidance, the market is paying a fair premium for quality rather than an irrational one. I lean bullish and would use weakness toward the 50-day SMA as an entry, while acknowledging the multiple leaves limited margin for error.

Calculated by applying a 32.5x forward P/E multiple to consensus forward adjusted EPS of $3.00. That multiple is a slight discount to EW's 5-year average P/E of 34.8x, justified by its premium 78% gross margin and 10%-11% organic growth but tempered by TAVR competition and high investor expectations.